USV has announced that the European Medicines Agency (EMA) has accepted for review its application for a proposed pegfilgrastim biosimilar.
USV has announced that the European Medicines Agency (EMA) has accepted for review its application for a proposed pegfilgrastim biosimilar.
Express Pharma reports that the Mumbai-based USV hopes to market the pre-filled syringe presentation of its pegfilgrastim biosimilar under the brand name Grasustek.
Prashant Tewari, MD, managing director of USV, told Express Pharma that “We are happy with the acceptance of our [application] by the EMA. USV has achieved a very significant milestone in the development program of Grasustek. We intend to provide high quality, affordable therapy options for cancer patients. We believe that Grasustek has potential life as well as cost-saving benefits for these patients.”
Filing of the application follows USV’s September 2017 announcement that it had successfully completed phase 1 and phase 3 studies on the proposed therapy. The phase 1 study compared the pharmacokinetics and pharmacodynamics of the biosimilar with the reference Neulasta at both a therapeutic dose and a low dose, and the phase 3 study followed 254 patients with breast cancer who were scheduled to undergo chemotherapy.
USV reports that, in addition to its clinical program to support submission of its application to the EMA, the company has begun planning for phase 1 development in the United States, and has held relevant meetings with the FDA. In India, USV has received approval to initiate phase 3 clinical studies for the proposed product.
USV joins fellow Indian drug maker Biocon in competing to receive the first European authorization for a pegfilgrastim biosimilar; Biocon announced in November 2017 that the EMA had accepted its resubmitted marketing authorization applications for a pegfilgrastim and a trastuzumab candidate (the recently FDA-approved Ogivri). Biocon had previously withdrawn its applications from the EMA to allow for a re-inspection of its manufacturing facility.
USV reports that is also developing biosimilars for somatropin, teriparatide, platelet-derived growth factor, filgrastim, glucagon, and epidermal growth factor.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.